• DVM360_Conference_Charlotte,NC_banner
  • ACVCACVC
  • DVM 360
  • Fetch DVM 360Fetch DVM 360
DVM 360
dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care
dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care
By Role
AssociatesOwnersPractice ManagerStudentsTechnicians
Subscriptions
dvm360 Newsletterdvm360 Magazine
News
All News
Association
Breaking News
Education
Equine
FDA
Law & Ethics
Market Trends
Medical
Politics
Products
Recalls
Regulatory
Media
dvm360 LIVE!™
Expert Interviews
The Vet Blast Podcast
Medical World News
Pet Connections
The Dilemma Live
Vet Perspectives™
Weekly Newscast
dvm360 Insights™
Publications
All Publications
dvm360
Firstline
Supplements
Vetted
Clinical
All Clinical
Anesthesia
Animal Welfare
Behavior
Cardiology
CBD in Pets
Dentistry
Dermatology
Diabetes
Emergency & Critical Care
Endocrinology
Equine Medicine
Exotic Animal Medicine
Feline Medicine
Gastroenterology
Imaging
Infectious Diseases
Integrative Medicine
Nutrition
Oncology
Ophthalmology
Orthopedics
Pain Management
Parasitology
Surgery
Toxicology
Urology & Nephrology
Virtual Care
Business
All Business
Business & Personal Finance
Hospital Design
Personnel Management
Practice Finances
Practice Operations
Wellbeing & Lifestyle
Continuing Education
Conferences
Conference Listing
Conference Proceedings
Upcoming dvm360 Conferences
Resources
CBD in Pets
CE Requirements by State
Contests
Partners
Spotlight Series
Team Meeting in a Box
Toolkit
Top Recommended Veterinary Products
Vet to Vet
Veterinary Heroes
  • Contact Us
  • Fetch DVM360 Conference
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Information
  • About Us

© 2023 MJH Life Sciences and dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care. All rights reserved.

Advertisement
By Role
  • Associates
  • Owners
  • Practice Manager
  • Students
  • Technicians
Subscriptions
  • dvm360 Newsletter
  • dvm360 Magazine
  • Contact Us
  • Fetch DVM360 Conference
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Information
  • About Us
  • MJHLS Brand Logo

© 2023 MJH Life Sciences™ and dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care. All rights reserved.

New FDA Plan Focuses on Plant and Animal Biotechnology

November 22, 2018
Amanda Carrozza

The plan’s key components are intended to ensure the safety of plant and animal biotechnology products. A December 3 informational webinar is planned.

The FDA has unveiled an action plan that outlines key priorities for the agency in supporting innovation in plant and animal biotechnology. According to the FDA’s announcement, the overarching goal of the Plant and Animal Biotechnology Innovation Action Plan is to ensure the safety of plant and animal biotechnology products while averting unnecessary barriers to future innovation.

“Innovations in plant and animal biotechnology offer tremendous opportunities for advancing public health,” FDA Commissioner Scott Gottlieb, MD, and Deputy Commissioner Anna Abram said in a joint statement. “Promising new technologies that can edit animal and plant genomes have the potential to improve human and animal health, animal well-being, food productivity, and food security. This new plan identifies priorities in 3 important areas:

  • Advancing human and animal health by promoting product innovation and applying modern, efficient, and risk-based regulatory pathways
  • Strengthening public outreach and communication regarding the FDA’s approach to innovative plant and animal biotechnology
  • Increasing engagement with domestic and international partners on biotechnology issues.”

Several action items in the plan may be of interest to the veterinary industry.

Veterinary Innovation Program

Advertisement

The FDA’s Center for Veterinary Medicine (CVM) launched a pilot of this program on October 30 to provide technical and programmatic assistance to developers of innovative veterinary products, including biotechnology products. The program offers tools meant to guide sponsors through the regulatory process, as well as options for developing alternative strategies for generating necessary evidence, pre-submission reviews of data packages, and cross-disciplinary and coordinated FDA review.

The FDA says the purpose of the innovation program is to enhance regulatory predictability and efficiency, improve agency responsiveness, and enable early, sustained interactions with innovators.

Genome Editing in Animals

On December 3, the CVM, along with representatives from FDA’s Center for Biologics Evaluation and Research, will host a public webinar to discuss the FDA’s regulatory approach. Registration for the webinar is required and attendees are encouraged to submit questions upon registering. This webinar is said to be the FDA’s initial step in helping innovators better understand how the agency’s regulatory oversight applies to their products.

“As a first step, the FDA will adopt a comprehensive policy framework for the development and regulatory oversight of animal biotechnology products, including for intentionally genetically altered animals and the food and drug products derived from them,” Dr. Gottlieb and Ms. Abram said. “This modern, flexible framework will advance the agency’s commitment to safety while promoting innovation in this space. Our shared goal is to help usher in new, beneficial and safe products to consumers and animals as quickly and safely as possible.”

FDA Guidance Documents

As part of its effort, the FDA plans to publish guidance documents over the next year in 2 key areas of animal biotechnology:

  • FDA’s regulatory approach and clear criteria and data requirements for each risk-based category
  • Use of genome editing techniques to produce new plant varieties for use in human or animal food.

“Another key focus of our Action Plan is a robust communications and engagement strategy designed to continue collaborations with a wide range of stakeholders to understand their views on how the FDA can best support safe innovation in plant and animal biotechnology while addressing and appropriately considering any potential risks,” Drs. Gottlieb and Abram explained.

One crucial area of collaboration that the FDA will address with domestic and international partners is how transformative biotechnology tools, such as gene drives, may eventually strengthen measures to address vector-borne diseases.


Advertisement

Latest News

3 Must-reads for National Pet Dental Health Month

Veterinary Dentistry Specialists first to apply human fracture repair technology to companion animals

Long Island University debuts College of Veterinary Medicine Learning Center

Paving the way for a more diversified veterinary profession

View More Latest News
Advertisement